a public good project by the
Synthesis
Company
of California

© 2026

Stephen A. Margosiak | doi.page

0 works0 citations0 h-index

Stephen A. Margosiak

Panthera Corporation(US)Panthera Biopartners(GB)PanThera Biopharma, LLC (United States)

Publications by Year

Research Areas

Biochemical and Molecular Research, Synthesis and Characterization of Heterocyclic Compounds, Bacterial Genetics and Biotechnology, Adenosine and Purinergic Signaling, Synthesis and biological activity

Most-Cited Works

→ Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials(1999)237 cited
→ Implications for Chk1 Regulation: The 1.7 Å Crystal Structure of Human Cell Cycle Checkpoint Kinase Chk1(2000)192 cited
→ Structure-Based Design, Synthesis, and Antimicrobial Activity of Indazole-Derived SAH/MTA Nucleosidase Inhibitors(2003)160 cited
→ Structure of the Human Cytomegalovirus Protease Catalytic Domain Reveals a Novel Serine Protease Fold and Catalytic Triad(1996)150 cited
→ Structure-based design of novel human Pin1 inhibitors (I)(2009)106 cited
→ Crystal Structure of Human ABAD/HSD10 with a Bound Inhibitor: Implications for Design of Alzheimer's Disease Therapeutics(2004)97 cited

→ Structure-Based Design, Synthesis, and Study of Potent Inhibitors of β-Ketoacyl-acyl Carrier Protein Synthase III as Potential Antimicrobial Agents(2005)

97 cited

→ Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities(2007)97 cited

→ Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2(2007)95 cited

→ AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies(1996)89 cited